{"pmid":32437739,"title":"Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.","text":["Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.","Cytokine release syndrome plays a crucial pathogenic role in COVID-19 pneumonia. This pilot study provides the first evidence of the safety of anti-IL-1 treatment with highdose IV anakinra in 5 patients, who experienced a positive outcome.","J Allergy Clin Immunol","Pontali, Emanuele","Volpi, Stefano","Antonucci, Giancarlo","Castellaneta, Marco","Buzzi, Davide","Tricerri, Francesca","Angelelli, Alessia","Caorsi, Roberta","Feasi, Marcello","Calautti, Francesca","Castagnola, Elio","Rollandi, Gian Andrea","Ravelli, Angelo","Cassola, Giovanni","Gattorno, Marco","32437739"],"abstract":["Cytokine release syndrome plays a crucial pathogenic role in COVID-19 pneumonia. This pilot study provides the first evidence of the safety of anti-IL-1 treatment with highdose IV anakinra in 5 patients, who experienced a positive outcome."],"journal":"J Allergy Clin Immunol","authors":["Pontali, Emanuele","Volpi, Stefano","Antonucci, Giancarlo","Castellaneta, Marco","Buzzi, Davide","Tricerri, Francesca","Angelelli, Alessia","Caorsi, Roberta","Feasi, Marcello","Calautti, Francesca","Castagnola, Elio","Rollandi, Gian Andrea","Ravelli, Angelo","Cassola, Giovanni","Gattorno, Marco"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437739","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jaci.2020.05.002","keywords":["covid-19","anakinra","cytokine release syndrome","interleukin-1","pneumonia"],"topics":["Treatment"],"weight":1,"_version_":1667521393753849856,"score":9.490897,"similar":[{"pmid":32411313,"pmcid":"PMC7221383","title":"FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.","text":["FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.","Dysregulation of inflammation is hypothesized to play a crucial role in the severe complications of COVID-19, with IL-1/IL-6 pathway being central. Here, we report on the treatment of eight severe COVID-19 pneumonia patients-- seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in the Netherlands-- with the interleukin-1 receptor antagonist Anakinra. All patients scored positive for the hemophagocytosis score (HScore) and were diagnosed with secondary hemophagocytic lymphohistocytosis (sHLH) characterized by pancytopenia, hyper-coagulation, acute kidney injury and hepatobiliary dysfunction. At the end-of-treatment, ICU patients had less need for vasopressors, significantly improved respiratory function and lower HScore. Although three patients died, the mortality was lower than historical series of patients with sHLH in sepsis. These data suggest that administration of Anakinra may be beneficial for treating severe COVID-19 patients with sHLH as determined by the HScore and support the need for larger clinical studies to validate this concept.","Cell Host Microbe","Dimopoulos, George","de Mast, Quirijn","Markou, Nikolaos","Theodorakopoulou, Maria","Komnos, Apostolos","Mouktaroudi, Maria","Netea, Mihai G","Spyridopoulos, Themistoklis","Verheggen, Rebecca J","Hoogerwerf, Jacobien","Lachana, Alexandra","van de Veerdonk, Frank L","Giamarellos-Bourboulis, Evangelos J","32411313"],"abstract":["Dysregulation of inflammation is hypothesized to play a crucial role in the severe complications of COVID-19, with IL-1/IL-6 pathway being central. Here, we report on the treatment of eight severe COVID-19 pneumonia patients-- seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in the Netherlands-- with the interleukin-1 receptor antagonist Anakinra. All patients scored positive for the hemophagocytosis score (HScore) and were diagnosed with secondary hemophagocytic lymphohistocytosis (sHLH) characterized by pancytopenia, hyper-coagulation, acute kidney injury and hepatobiliary dysfunction. At the end-of-treatment, ICU patients had less need for vasopressors, significantly improved respiratory function and lower HScore. Although three patients died, the mortality was lower than historical series of patients with sHLH in sepsis. These data suggest that administration of Anakinra may be beneficial for treating severe COVID-19 patients with sHLH as determined by the HScore and support the need for larger clinical studies to validate this concept."],"journal":"Cell Host Microbe","authors":["Dimopoulos, George","de Mast, Quirijn","Markou, Nikolaos","Theodorakopoulou, Maria","Komnos, Apostolos","Mouktaroudi, Maria","Netea, Mihai G","Spyridopoulos, Themistoklis","Verheggen, Rebecca J","Hoogerwerf, Jacobien","Lachana, Alexandra","van de Veerdonk, Frank L","Giamarellos-Bourboulis, Evangelos J"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32411313","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.chom.2020.05.007","keywords":["anakinra","covid-19","ferritin","hemophagocytic lymphohistocytosis","respiratory function"],"locations":["Greece"],"countries":["Greece"],"countries_codes":["GRC|Greece"],"topics":["Treatment"],"weight":1,"_version_":1666897319084163073,"score":206.79399},{"pmid":32422376,"title":"Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.","text":["Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.","We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.","Int J Infect Dis","Franzetti, Marco","Pozzetti, Ugo","Carugati, Manuela","Pandolfo, Alessandro","Molteni, Chiara","Faccioli, Paolo","Castaldo, Gioacchino","Longoni, Ernesto","Ormas, Valentina","Iemoli, Enrico","Piconi, Stefania","32422376"],"abstract":["We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection."],"journal":"Int J Infect Dis","authors":["Franzetti, Marco","Pozzetti, Ugo","Carugati, Manuela","Pandolfo, Alessandro","Molteni, Chiara","Faccioli, Paolo","Castaldo, Gioacchino","Longoni, Ernesto","Ormas, Valentina","Iemoli, Enrico","Piconi, Stefania"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422376","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.050","keywords":["anakinra","cytokine-release syndrome","interleukin-1 receptor antagonist","novel coronavirus disease 2019 (covid-19)","remdesivir"],"topics":["Case Report"],"weight":1,"_version_":1667159284442464256,"score":200.9626},{"pmid":32437934,"title":"Use of anakinra in severe COVID-19: a case report.","text":["Use of anakinra in severe COVID-19: a case report.","Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).","Int J Infect Dis","Filocamo, Giovanni","Mangioni, Davide","Tagliabue, Paola","Aliberti, Stefano","Costantino, Giorgio","Minoia, Francesca","Bandera, Alessandra","32437934"],"abstract":["Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra)."],"journal":"Int J Infect Dis","authors":["Filocamo, Giovanni","Mangioni, Davide","Tagliabue, Paola","Aliberti, Stefano","Costantino, Giorgio","Minoia, Francesca","Bandera, Alessandra"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437934","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.026","keywords":["anakinra","biologic","covid-19","il-1","treatment"],"topics":["Case Report"],"weight":1,"_version_":1667521393551474689,"score":196.94624},{"pmid":32482538,"pmcid":"PMC7183956","title":"Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19.","text":["Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19.","The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing acute respiratory distress syndrome (ARDS). This process is an inflammatory picture, involving an NLRP3 inflamosome-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. Anakinra is a potent biological drug, capable of blocking this IL-1ss. We propose its use in controlling ARDS secondary to COVID-19 infection.","Reumatol Clin","Munoz-Jimenez, Alejandro","Rubio-Romero, Esteban","Marenco de la Fuente, Jose Luis","32482538"],"abstract":["The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing acute respiratory distress syndrome (ARDS). This process is an inflammatory picture, involving an NLRP3 inflamosome-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. Anakinra is a potent biological drug, capable of blocking this IL-1ss. We propose its use in controlling ARDS secondary to COVID-19 infection."],"journal":"Reumatol Clin","authors":["Munoz-Jimenez, Alejandro","Rubio-Romero, Esteban","Marenco de la Fuente, Jose Luis"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482538","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.reuma.2020.04.009","keywords":["acute respiratory distress syndrome","anakinra","covid-19","il-1ss","inflamasoma","inflamosome","sindrome de distres respiratorio agudo"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668704334443970561,"score":186.9034},{"pmid":32441764,"title":"Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?","text":["Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?","Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well-tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of SARS-CoV-2 and combat the life-threatening sequelae of COVID-19 by several mechanisms. PARPi's can effectively decrease IL-6, IL-1 and TNFalpha levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic phenotype. PARPi's may also counteract SARS-CoV-2-induced and inflammation-induced cell death and support cell survival. PARPi's had beneficial effects in animal models of acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung injury. PARPi's may potentiate the effectiveness of Tocilizumab, Anakinra, Sarilumab, Adalimumab, Canakinumab or Siltuximab therapy. In summary, the evidence suggests that PARPi therapy would benefit COVID-19 patients and trials of these drugs should be undertaken.","Br J Pharmacol","Curtin, Nicola","Banyai, Krisztian","Thaventhiran, James","Le Quesne, John","Helyes, Zsuzsanna","Bai, Peter","32441764"],"abstract":["Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well-tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of SARS-CoV-2 and combat the life-threatening sequelae of COVID-19 by several mechanisms. PARPi's can effectively decrease IL-6, IL-1 and TNFalpha levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic phenotype. PARPi's may also counteract SARS-CoV-2-induced and inflammation-induced cell death and support cell survival. PARPi's had beneficial effects in animal models of acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung injury. PARPi's may potentiate the effectiveness of Tocilizumab, Anakinra, Sarilumab, Adalimumab, Canakinumab or Siltuximab therapy. In summary, the evidence suggests that PARPi therapy would benefit COVID-19 patients and trials of these drugs should be undertaken."],"journal":"Br J Pharmacol","authors":["Curtin, Nicola","Banyai, Krisztian","Thaventhiran, James","Le Quesne, John","Helyes, Zsuzsanna","Bai, Peter"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441764","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bph.15137","keywords":["ards","artd","adalimumab","anakinra","covid-19","il6","nad+","parp","parp inhibitor","sars-cov-2","sarilumab","siltuximab","tocilizumab","apoptosis","chloroquine","cytokine release syndrome","hydroxychloroquine","lopinavir","lung fibrosis","macrodomain","macrophage overactivation syndrome","mechanical ventilation","nicotinamide-riboside","olaparib","remedsivir","ritonavir","rucaparib","talazoparib"],"locations":["Siltuximab"],"e_drugs":["tocilizumab","siltuximab","sarilumab","Adalimumab","canakinumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119436480512,"score":180.95943}]}